Bausch + Lomb Says FDA Approved enVista Envy Full Range Of Vision Intraocular Lens
Portfolio Pulse from Benzinga Newsdesk
Bausch + Lomb announced that the FDA has approved its enVista Envy Full Range Of Vision Intraocular Lens (IOL). The product will be available in the U.S. on a limited basis soon, with broader availability expected in 2025. The company is also pursuing regulatory approvals in other markets.
October 14, 2024 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bausch + Lomb's enVista Envy IOL has received FDA approval, marking a significant milestone for the company. The product will be available in the U.S. soon, with broader distribution planned for 2025.
The FDA approval of the enVista Envy IOL is a positive development for Bausch + Lomb, as it allows the company to enter the U.S. market with this new product. The limited release followed by a broader rollout in 2025 suggests a strategic approach to market entry, which could positively impact the company's revenue and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100